-JNJ-31020028 Chemical Structure.png)
Physicochemical Properties
| Molecular Formula | C34H36FN5O2 |
| Molecular Weight | 565.680351257324 |
| Exact Mass | 565.285 |
| Elemental Analysis | C, 72.19; H, 6.41; F, 3.36; N, 12.38; O, 5.66 |
| CAS # | 1094873-17-2 |
| Related CAS # | JNJ-31020028;1094873-14-9 |
| PubChem CID | 25151876 |
| Appearance | Typically exists as solid at room temperature |
| Density | 1.2±0.1 g/cm3 |
| Boiling Point | 677.5±55.0 °C at 760 mmHg |
| Flash Point | 363.5±31.5 °C |
| Vapour Pressure | 0.0±2.1 mmHg at 25°C |
| Index of Refraction | 1.628 |
| LogP | 5.23 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 9 |
| Heavy Atom Count | 42 |
| Complexity | 857 |
| Defined Atom Stereocenter Count | 1 |
| SMILES | CCN(CC)C(=O)[C@@H](C1=CC=CC=C1)N2CCN(CC2)C3=C(C=C(C=C3)NC(=O)C4=CC=CC=C4C5=CN=CC=C5)F |
| InChi Key | OVUNRYUVDVWTTE-JGCGQSQUSA-N |
| InChi Code | InChI=1S/C34H36FN5O2/c1-3-38(4-2)34(42)32(25-11-6-5-7-12-25)40-21-19-39(20-22-40)31-17-16-27(23-30(31)35)37-33(41)29-15-9-8-14-28(29)26-13-10-18-36-24-26/h5-18,23-24,32H,3-4,19-22H2,1-2H3,(H,37,41)/t32-/m1/s1 |
| Chemical Name | N-[4-[4-[(1R)-2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl]-3-fluorophenyl]-2-pyridin-3-ylbenzamide |
| Synonyms | (R)-JNJ31020028; (R)-JNJ-31020028; JNJ31020028; (R)-N-(4-(4-(2-(diethylamino)-2-oxo-1-phenylethyl)piperazin-1-yl)-3-fluorophenyl)-2-(pyridin-3-yl)benzamide; CHEMBL1823577; N-[4-[4-[(1R)-2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl]-3-fluorophenyl]-2-pyridin-3-ylbenzamide; SCHEMBL1174048; BCP14605; (R) JNJ-31020028 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | rat Y2 receptor ( pIC50 = 8.22 ); human Y2 receptor ( pIC50 = 8.07 ) |
| ln Vitro | In vitro activity: JNJ-31020028 is tested by binding to a panel of 50 receptors, ion channels, and transporters, such as adenosine (A1, A2A, A3), adrenergic (α1, α2, β1), angiotensin (AT1), dopamine (D1, D2), bradykinin (B2), cholecystokinin (CCKA), galanin (GAL2), melatonin (ML1), muscarinic (M1, M2, M3), neurotensin (NT1), neurokinin (NK2, NK3), opiate (μ, κ, δ), serotonin (5-HT1A, 5-HT1B, 5-HT2A, 5-HT3, 5-HT6, 5-HT7), somatostatin, vasopressin (V1a), norepinephrine transporter, dopamine transporter, and ion channels (sodium, calcium, potassium, and chloride). Except for the Y2 receptor, the Y2 antagonist exhibits no discernible affinity (<50% inhibition at 10μM) for any other receptor, transporter, or ion channel at concentrations up to 10μM. The Y2 antagonist's selectivity is assessed in more detail using a panel of 65 kinases. JNJ-31020028 (10μM) does not inhibit any of the panel's kinases[1]. |
| ln Vivo | In the olfactory bulbectomized rat (OBX) model, (R)-JNJ-31020028 (5.6 μg; chronic intravenous infusion; once daily for 10 days) demonstrates antidepressant-like effects [1]. The number of grooming episodes was significantly reduced by administering (R)-JNJ-31020028 intravenously over an extended period of time using an osmotic Alzet pump at a dose of 5.6 μg/day [1]. Treatment with (R)-JNJ-31020028 revealed Cmax, Tmax, AUCinf, Vd, and t1/2 values of 4.35μM, 0.5 hours, 7.91hμM, and 0.83 hours, in that order [1]. |
| Enzyme Assay |
In functional assays, JNJ-31020028 was shown to be an antagonist (pK(B) = 8.04 +/- 0.13). Radioligands binding assays[1] Competition binding assays were performed as previously described (Bonaventure et al. 2004) using [125I]PYY for Y1, Y2, and Y5 receptor and [125I]PP for Y4 receptor. Cells used in the radioligand binding experiments with NPY receptor subtypes were SK-N-MC endogenously expressing Y1 receptors, KAN-Ts endogenously expressing Y2 receptors, Chinese hamster ovary (CHO) cells transfected with human Y4 cDNA for Y4 receptors, and HEK-293 transfected with human Y5 cDNA for Y5 receptors. Membranes from rat and mouse hippocampus were also prepared and assayed for [125I]PYY binding as previously described (Bonaventure et al. 2004). IC50 values (i.e., concentration of unlabeled antagonist required to compete for 50% of specific binding to the radioligand) were calculated using the GraphPad Prism software with a fit to a sigmoidal dose–response curve. Data were expressed as pIC50 values where pIC50 = −log IC50. In addition, the selectivity of JNJ-31020028 was evaluated in a large variety of ion channels, transporters, receptor binding, and kinase assays.[1] |
| Cell Assay | Calcium mobilization assays[1] A calcium mobilization assay was established by stably expressing a chimeric G protein Gqi9 in KAN-Ts cells endogenously expressing Y2 receptors as previously described (Dautzenberg 2005). Briefly, dye-loaded cells were plated on to 96-well ViewPlates and incubated at 37°C, 5% CO2 for 1 h. For antagonist potency determinations, cells were pre-incubated with the compounds (diluted in Dulbecco’s modified Eagle medium/F-12) for 10 min before agonist (PYY 10 nM) stimulation. Ligand-induced calcium release was measured using a Fluorometric Imaging Plate Reader. Functional responses were measured as peak fluorescence intensity minus basal. The concentration of agonist that produced a half-maximal response is represented by the EC50 value. Antagonistic potency values were converted to apparent pKB values using a modified Cheng–Prusoff correction. Apparent pKB = −log IC50/1 + [conc agonist/EC50]. Data are expressed as mean ± SEM. |
| Animal Protocol |
Animal/Disease Models: Male Sprague Dawley rats, body weight 150-170 (OBX model) [1] Doses: 5.6 μg Route of Administration: chronic intravenous (iv) (iv)infusion; one time/day for 10 days Experimental Results: diminished immobility time in OBX rats. Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rat [2] Doses: 10 mg/kg Route of Administration: subcutaneous injection (pharmacokinetic/PK/PK analysis) Experimental Results: Cmax, Tmax, AUCinf, Vd and t1/2 were 4.35 μM, 0.5 respectively hrs (hrs (hours)), 7.91 h μM and 0.83 h respectively. |
| References |
[1]. In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y. [2]. Chronic administration of the Y2 receptor antagonist, JNJ-31020028, induced anti-depressant like-behaviors in olfactory bulbectomized rat. Neuropeptides. 2012 Dec;46(6):329-34. |
| Additional Infomation |
Rationale: The lack of potent, selective, brain penetrant Y(2) receptor antagonists has hampered in vivo functional studies of this receptor.
Objective: Here, we report the in vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a novel Y(2) receptor antagonist.
Methods: The affinity of JNJ-31020028 was determined by inhibition of the PYY binding to human Y(2) receptors in KAN-Ts cells and rat Y(2) receptors in rat hippocampus. The functional activity was determined by inhibition of PYY-stimulated calcium responses in KAN-Ts cells expressing a chimeric G protein Gqi5 and in the rat vas deferens (a prototypical Y(2) bioassay). Ex vivo receptor occupancy was revealed by receptor autoradiography. JNJ-31020028 was tested in vivo with microdialysis, in anxiety models, and on corticosterone release.
Results: JNJ-31020028 bound with high affinity (pIC(50) = 8.07 +/- 0.05, human, and pIC(50) = 8.22 +/- 0.06, rat) and was >100-fold selective versus human Y(1), Y(4), and Y(5) receptors. JNJ-31020028 was demonstrated to be an antagonist (pK(B) = 8.04 +/- 0.13) in functional assays. JNJ-31020028 occupied Y(2) receptor binding sites (approximately 90% at 10 mg/kg) after subcutaneous administration in rats. JNJ-31020028 increased norepinephrine release in the hypothalamus, consistent with the colocalization of norepinephrine and neuropeptide Y. In a variety of anxiety models, JNJ-31020028 was found to be ineffective, although it did block stress-induced elevations in plasma corticosterone, without altering basal levels, and normalized food intake in stressed animals without affecting basal food intake.
Conclusion: These results suggest that Y(2) receptors may not be critical for acute behaviors in rodents but may serve modulatory roles that can only be elucidated under specific situational conditions.[1] Recent studies from our groups have shown that BIIE0246, a Y2 receptor antagonist, has antidepressant effect in olfactory bulbectomized (OBX) rat. However, its complex structure and high molecular weight limit its usefulness as an in vivo pharmacological tool. Alternatively, the novel and brain penetrant Y2 receptor antagonist, JNJ-31020028 is a useful tool to investigate the in vivo function of the Y2 receptor. In the present study, we evaluated the effect of chronic intracerebroventricular (icv) administration of JNJ-31020028 in a battery of behavioral tests in an animal model that mimics several deficits observed in the human depression, the OBX rat. Chronic administration of JNJ-31020028 induced a decrease in immobility time in the forced swim test in OBX while had no effect in control animals. Additionally, it decreased number of grooming events in OBX animals, but had no effects on some other behavioral deficits observed such as rearing and hyperlocomotion. Furthermore, JNJ-31020028 had no effect on behavior tests that are commonly used to evaluate anxiety, namely the social interaction test in both OBX and control animals. These data indicate that similar to BIIE0246, JNJ-31020028 also has antidepressant like effects in the OBX model.[2] |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7678 mL | 8.8389 mL | 17.6778 mL | |
| 5 mM | 0.3536 mL | 1.7678 mL | 3.5356 mL | |
| 10 mM | 0.1768 mL | 0.8839 mL | 1.7678 mL |